Objective 
Introduction

According to the Japanese Ministry of Health, Labour and Welfare (MHLW), pneumonia is the fourth leading cause of death in Japan. If deaths from pneumonia are analyzed by age, elderly patients (aged > 65 years) account for >90% of total deaths from pneumonia (1). The high death rate among elderly patients with pneumonia is primarily attributable to the following factors: 1) elderly individuals are prone to infection due to compromised immune function caused by underlying disease, malnutrition, etc.; and 2) occult misswallowing and reduced drug absorption due to cerebrovascular disease and dementia (2, 3). Because pneumonia in elderly individuals tends to follow severe courses under the influence of these factors, drugs with potent and broad-spectrum antimicrobial activity (e.g., cephalosporins, carbapenems) are often used to manage elderly patients with pneumonia. In recent years, however, narrow-spectrum antimicrobial agents have been recommended for more widespread use due to their improved medical economics and as a result of bacterial resistance to broad-spectrum antimicrobial agents (4). Under such circumstances, the clinical usefulness of the penicillins has been reviewed, and the use of ampicillin (ABPC) in combination with beta-lactamase inhibitors is
. In Japan, the Japanese Respiratory Society (JRS) proposed guidelines in 2000 (10) .
The 
Subjects and Methods
Participating facilities
Discontinuation of treatment
Treatment was discontinued if underlying disease or infection was exacerbated, if efficacy of treatment was inadequate or condition was exacerbated, if complications were exacerbated, if incidental symptoms developed, if adverse reactions or laboratory abnormalities developed, if the patient or his/her proxy requested discontinuation, or if the attending physician considered discontinuation necessary for other reasons. Data from discontinued cases were included, if clinical evaluation was possible at the time of discontinuation.
Evaluation
Severity of pneumonia was rated based on the attending physician's subjective judgment, in addition to the Pneumonia Severity Index (PSI) prepared by the Infectious Disease
Society of America (IDSA) (9) 
received SBT/ABPC therapy and the remaining 32 received IPM/CS therapy. The four cases excluded from efficacy evaluation included one patient with interstitial pneumonia from the SBT/ABPC therapy group and 3 patients from the IPM/CS therapy group (one with acute exacerbation of chronic obstructive pulmonary disease, one with cardiac failure, and one with a disease not covered by this study). There was no significant difference between the SBT/ABPC therapy group and the IPM/CS therapy group with regard to background variables such as sex, age, JRS severity rating, PSI severity rating, underlying disease, complications, disease history, allergy or history of pneumococcal vaccination (Table 1). The most frequent underlying disease or complication was pulmonary emphysema (including chronic obstructive pulmonary disease), which was seen in 19 cases. Other frequent underlying diseases and complications were diabetes mellitus (11 cases), malignant diseases (malignant tumors, leukemia, etc.; 10 cases), pulmonary tuberculosis (including old tuberculosis; 7 cases), cardiac dis-
F i g u r e 1 . Ov e r a l l c l i n i c a l o u t c o me a f t e r s u l b a c t a m/ a mp ic i l l i n ( S B T / AB P C) o r i mi p e n e m/ c i l a s t a t i n ( I P M/ CS ) t r e a tme n t . E f f i c a c y r a t e ( i mp r o v e me n t + c u r e ) wa s 9 1 . 4 % i n t h e S B T / AB P C-t r e a t e d g r o u p a n d 8 7 . 5 % i n t h e I P M/ CS -t r e a t e d g r o u p . Table 2 .
eases (7 cases), cerebrovascular diseases (6 cases), dementia (3 cases), and others (43 cases). Some patients had two or more underlying diseases or complications. Six patients were free of underlying disease and complications. With regard to distribution of each underlying disease or complication, there were no significant differences between the SBT/ ABPC and IPM/CS groups. The most frequent pathogen was S. pneumoniae (19 cases), followed by Pseudomonas aeruginosa (7 cases), methicillin-susceptible Staphylococcus aureus (MSSA; 6 cases) and H. influenzae (6 cases), as shown in
Overall clinical efficacy
The efficacy rate was 91. 4% (32/35) (2, 11, 12) (15) . PSI, on the other hand, adopted criteria developed by PORT (9) 
